Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016

GAITHERSBURG, Md., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a...
September 30, 2016 09:28 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC

GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement...
September 30, 2016 09:04 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 Billion

GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a multi-year contract with the Biomedical Advanced Research and...
August 15, 2016 16:20 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55

GAITHERSBURG, Md., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental...
August 12, 2016 16:50 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics

GAITHERSBURG, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that, as a result of the completion of the spin-off of Aptevo Therapeutics, the...
August 10, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin

GAITHERSBURG, Md., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option...
August 04, 2016 16:15 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results

GAITHERSBURG, Md., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2016. FINANCIAL HIGHLIGHTS ...
August 01, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics

GAITHERSBURG, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc....
July 21, 2016 16:15 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016

GAITHERSBURG, Md., July 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the...
July 20, 2016 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock

GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc....